Invizyne Technologies Common Stock (IZTC) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with IZTC included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

FAQ

  • What is the primary business of Invizyne Technologies Common Stock?
  • What is the ticker symbol for Invizyne Technologies Common Stock?
  • Does Invizyne Technologies Common Stock pay dividends?
  • What sector is Invizyne Technologies Common Stock in?
  • What industry is Invizyne Technologies Common Stock in?
  • What country is Invizyne Technologies Common Stock based in?
  • Is Invizyne Technologies Common Stock in the S&P 500?
  • Is Invizyne Technologies Common Stock in the NASDAQ 100?
  • Is Invizyne Technologies Common Stock in the Dow Jones?
  • When does Invizyne Technologies Common Stock report earnings?

What is the primary business of Invizyne Technologies Common Stock?

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

What is the ticker symbol for Invizyne Technologies Common Stock?

The ticker symbol for Invizyne Technologies Common Stock is NASDAQ:IZTC

Does Invizyne Technologies Common Stock pay dividends?

No, Invizyne Technologies Common Stock does not pay dividends

What sector is Invizyne Technologies Common Stock in?

Invizyne Technologies Common Stock is in the Healthcare sector

What industry is Invizyne Technologies Common Stock in?

Invizyne Technologies Common Stock is in the Biotechnology industry

What country is Invizyne Technologies Common Stock based in?

Invizyne Technologies Common Stock is headquartered in United States

Is Invizyne Technologies Common Stock in the S&P 500?

No, Invizyne Technologies Common Stock is not included in the S&P 500 index

Is Invizyne Technologies Common Stock in the NASDAQ 100?

No, Invizyne Technologies Common Stock is not included in the NASDAQ 100 index

Is Invizyne Technologies Common Stock in the Dow Jones?

No, Invizyne Technologies Common Stock is not included in the Dow Jones index

When does Invizyne Technologies Common Stock report earnings?

The date for Invizyne Technologies Common Stock's next earnings report has not been announced yet